Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

India's Premier Medical Corporation's COVID-19 Antigen Test Receives World Health Organization Emergency Use Listing Worldwide


News provided by

Premier Medical Corporation

07 Apr, 2021, 10:00 IST

Share this article

Share toX

Share this article

Share toX

SARIGAM, GUJARAT, India, April 7, 2021 /PRNewswire/ -- Premier Medical Corporation (PMC) – a leading manufacturer of COVID-19 Antigen and Antibody testing – has been placed on the Emergency Use Listing (EUL) by the World Health Organization (WHO) to allow for worldwide procurement.

It is just the third company in the world, and the only Indian-based company, to accomplish this feat. The tests were entirely developed and manufactured in India.

It comes after the Indian Council of Medical Research (ICMR) approved the Sure Status COVID-19 Antigen Card Test for immediate use in India last year. The tests are already currently in use in the country.

The company plans to now submit the COVID-19 Antigen test to the U.S. Food and Drug Administration (FDA) for inclusion under the Emergency Use Authorization (EUA) program.

The simple and affordable test is performed by taking a sample from your nose to determine if it contains viral genetic material, giving results in just about 15 minutes. The specificity is 100% and the sensitivity is 94.5%. This makes it possible to quickly and conveniently test people in a variety of settings, including schools, workplaces and doctor's offices without the need for additional equipment.

The company is also currently in the process of developing a test for the detection of other variants of COVID-19 based on its patented platform technology and rapid saliva testing, which would be a key part of bringing the virus and its transmission under control.

Premier Medical Corporation is a global leader in developing, manufacturing and distributing diagnostic testing for infectious diseases, including for HIV, Malaria, Hepatitis and Syphilis. It has collaborated with leading universities and the Centers for Disease Control to develop novel tests for various infectious diseases.

The company currently employs more than 500 people at its manufacturing facility in the State of Gujarat. 

For additional information, please contact: [email protected].

For press inquiries, please contact Natasha Alagarasan at [email protected].

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.